卵巢癌肉瘤最新治療方法

The novel treatment of ovarian carcinosarcoma

卵巢癌肉瘤又稱卵巢惡性混合繆勒氏瘤、卵巢類肉瘤癌或卵巢惡性混合中胚層瘤，乃一種高度惡性腫瘤，佔所有惡性卵巢腫瘤1-4%。治療主要先行減積手術，再追加化學藥物治療，由於此腫瘤患者少見，尚未有手術後統一的輔助治療。有些研究認為PARP抑制劑、抗體藥物複合體和免疫治療有不錯的效果，但我們認為須建立國際間資料庫，來評估這些新的治療方法對卵巢癌肉瘤的成果再決定。

Ovarian carcinosarcoma, also termed ovarian malignant mixed mesodermal tumors(MMMTs), ovarian sarcomatoid carcinoma, or ovarian malignant mixed mullerian tumors are highly virulent, and comprise 1-4% of ovarian malignancies. These patients are recommended to treat with optimal cytoreduction surgery followed by chemotherapy(carboplatin and paclitaxel). No definitive conclusion regarding postoperative adjuvant therapy can be drawn because of the rarity of the lesion and the small number of patients undergoing a particular therapy. Several studies have suggested that PARP inhibitors, ADC and immunotherapy have activity in this disease. We would like to emphasize the importance of creating an international database of ovarian carcinosarcomas which would make it possible to obtain the result of the novel treatment.